The Cooper Companies, Inc. · NASDAQ:COO
The Cooper Companies — Cooper Companies — Merger or Acquisition (February 2022)
7 slides from The Cooper Companies's merger presentation, Feb 7, 2022
Slide 1: CooperCompanies Acquisition of Cook Medical's Reproductive Health Business
CooperCompanies Acquisition of Cook® Medical’s Reproductive Health Business February 7, 2022 Exhibit 99.2
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Statements relating to guidance, plans, prospects, goals, strategies, future actions, events or performance and other statements of which are other t
Slide 3: Cooper to Acquire Cook Medical Reproductive Health
Cook Medical Reproductive Health Manufactures and sells minimally invasive medical devices focused on fertility, obstetrics and gynecology markets Calendar 2021 Sales: ~$158M (~73% fertility/~27% ObGyn), up ~17% YoY cc1 Deal Terms Purchase Price: ~$875M comprised of $675M at closing and $200M paid i
Slide 4: Compelling Strategic Rationale
Geographic expansion Expands fertility in several Asia Pac countries (currently under-indexed) Accelerates opportunities in China Significantly enhances direct selling opportunities for ObGyn medical devices in EMEA and Asia Pac Expands CSI labor & delivery Adds complementary, well-established devic
Slide 5: Fertility Industry Highlights
Pipettes Needles Fertility Industry Highlights Growth Drivers: Increasing maternal age Greater access to treatment Increased patient awareness/comfort Greater worldwide disposable income Up to 1 in 8 couples suffer from infertility worldwide $1.8B+ Global Market1 5-10% Annual Growth Manufacturer sal
Slide 6: Cook Adds High Quality ObGyn Medical Devices
Cook® Medical Reproductive Health Adds high quality ObGyn medical devices ObGyn Product Portfolio Strategic Fit CSI’s Obstetrics Portfolio: Growing portfolio of obstetrics products is highly complementary to broader ObGyn medical device portfolio Includes devices for vacuum-assisted delivery, fetal
Slide 7: Compelling Financial Rationale
Complementary revenue growth rates Expected long-term revenue growth: 5-9% (fertility 5-10%, ObGyn 4-6%) Strong margins Similar to existing consolidated gross margins Accretive to consolidated operating margins Accretive to Non-GAAP EPS Expected to be ~$0.60 accretive in year 1; further accretive th
Cooper Companies — Merger or Acquisition (February 2022) on 6ix